BioTheryX, Inc. is a San Diego-based company specializing in the development of first-in-class protein degraders for the treatment of cancer and inflammatory diseases. With their PRODEGY Protein Degrader Technology platform, they are at the forefront of targeted protein degradation drug discovery, leveraging their expertise in modulating Cereblon to design unique and powerful drug candidates.
Driven by their mission to degrade proteins and save lives, BioTheryX is building a pipeline of innovative protein degraders, including molecular glues and bifunctional degraders, with a focus on oncology and inflammatory disorders. Their groundbreaking research collaborations, preclinical findings, and participation in industry events demonstrate their commitment to transforming patient treatment through the development of novel therapies.
Generated from the website